(Q37869439)

24 August 2017

1 reference

title

A clinical perspective of IL-1β as the gatekeeper of inflammation (English)

1 reference

24 August 2017

0 references

1

Charles A Dinarello

1 reference

PubMed ID

21523780

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

European Journal of Immunology

24 August 2017

1 reference

24 August 2017

41

1 reference

24 August 2017

5

1 reference

24 August 2017

1203-1217

1 reference

IL-1: discoveries, controversies and future directions

24 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Human leukocytic pyrogen: purification and development of a radioimmunoassay

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1 and the Pathogenesis of the Acute-Phase Response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Cloning and expression of murine interleukin-1 cDNA in Escherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Beneficial response to interleukin 1 receptor antagonist in traps

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Mitochondria: Sovereign of inflammation?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Identification of a key pathway required for the sterile inflammatory response triggered by dying cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

An autoinflammatory disease due to homozygous deletion of the IL1RN locus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Neurologic manifestations of the cryopyrin-associated periodic syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Colchicine therapy for familial mediterranean fever. A double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Lessons from anti-TNF biologics: infliximab failure in a TRAPS family with the T50M mutation in TNFRSF1A.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Clinical and radiological effects of anakinra in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra for rheumatoid arthritis: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Blockade of TNF-α rapidly inhibits pain responses in the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The German etanercept registry for treatment of juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Isolation of an interleukin-1-like factor from human joint effusions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

IL-1 inhibition with anakinra in a patient with refractory gout

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Update on gout: new therapeutic strategies and options

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Successful treatment of chronic tophaceous gout with infliximab (Remicade)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Cytokines and beta-cell biology: from concept to clinical translation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Disease-associated amyloid and misfolded protein aggregates activate the inflammasome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The role of interleukin-1 beta in the pathogenesis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The Schnitzler syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra for flares of pyogenic arthritis in PAPA syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

A case of refractory adult-onset Still's disease treated with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

May anakinra be used earlier in adult onset Still disease?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Schnitzler syndrome: treatment failure to rituximab but response to anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

A case of macrophage activation syndrome successfully treated with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Non‐complementaemic urticarial vasculitis: successful treatment with the IL‐1 receptor antagonist, anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

[Indications of anakinra]

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Resistant Behçet disease responsive to anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Case of anakinra as a steroid-sparing agent for gout inflammation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141550

7 January 2021

Identifiers

DOI

10.1002/EJI.201141550

1 reference

24 August 2017

1 reference

PubMed ID

21523780